Skip to main content

Table 4 Changes of the echocardiographic findings in patients without cancer therapeutics-related cardiac dysfunction

From: Left atrial longitudinal strain as a predictor of Cancer therapeutics-related cardiac dysfunction in patients with breast Cancer

  Baseline After chemotherapy After trastuzumab therapy
LVEDVI (mL/m2) 56.5 ± 9.9 55.9 ± 10.2 55.7 ± 10.3
LVESVI (mL/m2) 20.3 ± 4.6 20.0 ± 5.1 20.2 ± 5.7
LVEF (%) 63.9 ± 5.9 64.2 ± 6.7 63.8 ± 7.3
LVGLS (%) −22.2 ± 2.2 −20.2 ± 2.2* −17.8 ± 2.3†‡
E (cm/sec) 62.7 ± 7.7 61.4 ± 11.6 59.2 ± 11.8
e’ (cm/sec) 8.3 ± 1.8 8.3 ± 1.7 7.9 ± 1.7
s’ (cm/sec) 7.4 ± 1.0 7.3 ± 1.0 7.3 ± 1.1
E/e’ 7.7 ± 1.2 7.6 ± 1.5 7.7 ± 1.8
LAVI (mL/m2) 26.0 ± 3.9 26.1 ± 4.1 26.7 ± 4.0
PALS (%) 33.8 ± 5.6 30.9 ± 5.7* 28.0 ± 6.0†‡
LA conduit strain (%) 19.8 ± 3.3 16.6 ± 3.0* 15.0 ± 3.2†‡
LA booster strain (%) 14.0 ± 2.3 14.3 ± 2.7 13.0 ± 2.8†‡
RVSP (mmHg) 32.0 ± 7.3 30.8 ± 7.7 29.2 ± 8.1
  1. LVEDVI left ventricular end-diastolic volume index, LVESVI left ventricular end-systolic volume index, LVEF left ventricular ejection fraction, LVGLS left ventricular global longitudinal strain, E: early diastolic mitral inflow velocity, e’: early diastolic velocity of mitral septal annulus, s’: systolic velocity of mitral septal annulus, LAVI left atrial volume index, PALS peak atrial longitudinal strain, LA left atrium, RVSP right ventricular systolic pressure. *: p < 0.05 between baseline and after chemotherapy, †: p < 0.05 between after chemotherapy and after trastuzumab therapy, ‡: p < 0.05 between baseline and after trastuzumab therapy